Top 50 Life Science Startup Investors in United States in October 2023

Portfolio highlights

• AIRNA — AIRNA is on a mission to transform the lives of patients with rare and common diseases by pioneering thediscovery and development of RNA editing therapeutics.
• Generate Biomedicines — Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines.
• Lightcast Discovery — Flexible control over droplet number, occupancy, location and movement. Enabling efficient, multi-step workflows with unprecedented flexibility.

Portfolio highlights

• Octave — Octave has developed the first of it's kind precision care solution focused on neurodegenerative diseases beginning with Multiple Sclerosis (MS).
• Sound Agriculture — Sound Agriculture is creating a more agile and resilient food system with innovative on-demand crop solutions.
• Slingshot Biosciences — Precise, reliable, and repeatable results. With synthetic cell controls, these goals are achievable in your flow cytometry experiments. Reduce costs, save time and commercialize faster. Beads for spectral compensation, immunophenotyping, viability, and assay controls.

Portfolio highlights

• Deka Biosciences — Deka BioSciences, Inc. is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases.
• Solu Therapeutics — Solu Therapeutics is a precision-medicine-focused company developing therapeutics to eliminate disease-driving cells.
• Arialys Therapeutics — Arialys Therapeutics is a pre-clinical stage company that develops auto-antibody focusing on neuroscience. The company focuses on how the immune system impacts CNS health, disease, and treatment.

Portfolio highlights

• Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
• Hepalink — Hepalink is a manufactures ultra-pure pipeline control systems based on semiconductors and pan-semiconductor liquid circuits.
• Mediar Therapeutics — Mediar Therapeutics is a preclinical stage biotechnology company developing antibody-based therapeutics to halt fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.

Portfolio highlights

• Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
• Adela — Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test.
• SAB Biotherapeutics — A biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems,rare conditions, long-term diseases and global pandemic threats.

Portfolio highlights

• Gridware — Using remote telemetry and edge AI, Gridware wildfire prevention technology powers a grid that is smarter and more reliable than ever before.
• BIOS — BIOS Health is unlocking the potential of the nervous system in treating chronic disease by using AI-powered neural interfaces that can automatically read and write neural signals.
• Elicit — Elicit is an artificial intelligence research assistant that uses language models to help users automate research workflows. This research assistant finds relevant papers without a perfect keyword match, summarizes takeaways from the papers, and extracts key information from the papers.

Portfolio highlights

• Aryn — Answer questions on all of your data.
• ClearFeed — Conversational Support Platform on Slack
• Reserv — We are a premier claims platform, born from state-of-the-art data intelligence and talent management technology.

Portfolio highlights

• Deka Biosciences — Deka BioSciences, Inc. is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases.
• ReCode Therapeutics — ReCode is the first genetic medicines platform to enable highly targeted delivery to organs, tissues and cells beyond the liver. Our pipeline of rare disease therapeutics uses optimized mRNA and gene correction with redosing capability.
• Arialys Therapeutics — Arialys Therapeutics is a pre-clinical stage company that develops auto-antibody focusing on neuroscience. The company focuses on how the immune system impacts CNS health, disease, and treatment.

Portfolio highlights

• K36 Therapeutics — K36 Therapeutics mission to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapies.
• Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
• Nvelop Therapeutics — Nvelop Therapeutics is a biotechnology company that provides gene editing technology services for unmet major disease needs.

Portfolio highlights

• Flare Therapeutics — Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Our drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation.
• Rapport Therapeutics — Precision medicines to match the complexity of the human brain.
• CARGO Therapeutics — CARGO Therapeutics develops CAR T-cell therapy to overcome cancer treatment resistance and address access barriers so that more patients can benefit from potentially curative therapies. The company is on a mission to outwit cancer by developing best-in-class chimeric antigen receptor (CAR) T-cell therapies. Despite commercially available autologousCARs advancements, these treatments are curative for less than half of all cancer patients. Furthermore, far too many patients are unable to access these potentially curative therapies due to other obstacles such as manufacturing, supply constraints, long turnaround times, and reimbursement barriers. CARGO's team is intensely focused on pursuing novel solutions to improve cancer treatment outcomes and experiences.

Portfolio highlights

• Evozyne — We have a new way of thinking about proteins. We've uncovered Nature's hidden rules to build Natural Machines. With our partners, we are changing the world.
• Adela — Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test.
• Iambic Therapeutics — Iambic has created a cutting-edge AI-driven platform to tackle the most challenging design problems in drug discovery and address unmet patient need.

Portfolio highlights

• Spruce Biosciences — Developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need
• Nvelop Therapeutics — Nvelop Therapeutics is a biotechnology company that provides gene editing technology services for unmet major disease needs.
• Novome Biotechnologies — Novome Biotechnologies, Inc. is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered MicrobialMedicines (GEMMs). Novome is utilizing its proprietary GEMMs platform in its lead preclinical program in hyperoxaluria, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to prevent the formation of kidney stones. Efforts are also directed to the expansion of its proprietary synthetic biology platform into additional indications.

Portfolio highlights

• Cardiosense — Cardiosense offers a physiological waveform AI platform to develop predictive biomarkers for the detection and treatment of disease. Its platform leverages multi-modal sensors and industry-leading AI to develop predictive biomarkers for the detection and treatment of disease.
• Aer Therapeutics — Aer Therapeutics is a clinical stage biopharmaceutical company developing a novel inhaled approach to treat lung disease with excess mucus and mucus plugs.
• Mercy BioAnalytics — We are making early stage cancer 100,000x easier to find using extracellular vesicles found in blood, specific to their parent cells.

Portfolio highlights

• Xilis — Xilis is an oncology and precision health company that diagnoses cancer and finds the right treatment. The company uses “micro-organoids” to make thousands of 3D replicas of a patient’s tumor in about six days, which the company says can be used for testing for drug compatibility faster. It was founded in 2019 and is headquartered in Durham,North Carolina.
• Endpoint Health — Endpoint Health is a precision-first therapeutics company. By rewriting the molecule-first drug development model, we aim to deliver precision therapies that have the potential to improve outcomes for patients with immune-driven illnesses.
• 64x Bio — 64x Bio builds a platform that increases the speed and scale of mammalian cell line discovery.The company uses a throughput discovery and screening platform and an integrated computational design loop, they develop new ways of generating highly optimized and otherwise unattainable cell lines for the manufacturing of viral vectors, with a specificfocus on those used for cell and gene therapies.

Portfolio highlights

• Noetik — Noetik is an AI-native biotechnology company. Our mission is to leverage advanced machine learning methods to discover and develop cancer immunotherapies.
• CH4 Global — CH4 Global is bending the curve with climate change solutions. We leverage red seaweed to help with methane reduction. Learn more our AgTech Solutions today!
• Mach Industries — Delivering decentralized warfare capabilities to guarantee the defense of freedom.

Portfolio highlights

• Kate Therapeutics — Kate Therapeutics is a patient-focused biotechnology company developing AAV-based gene therapies to treat genetically defined muscle and heart diseases.
• Nexo Therapeutics — Nexo Therapeutics is a small molecule oncology company dedicated to the discovery and development of new drugs for cancer patients who currently lack meaningful therapies.
• Tentarix Biotherapeutics — Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology. The company develops a protein engineering platform designed for multispecific therapies.

Portfolio highlights

• Andes — Andes empowers microbes to enable positive action against climate change.
• Dimension Inx — Dimension Inx focuses on creating advanced biomaterials and 3D-printed implants that fundamentally change human disease and debilitation. It specializes in the fields of additive manufacturing, 3D-printing, biomaterials, and manufacturing. It was founded in 2017 and headquartered in Chicago, Illinois.
• SURGE Therapeutics — SURGE Therapeutics seeks to dramatically improve cancer patient survival by disrupting cancer immunotherapy is deployed.

Portfolio highlights

• Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
• Avalyn Pharma — This does NOT display on the home page
• Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.

Portfolio highlights

• Monod Bio — Monod Bio l Simple. Powerful. Biosensors for Medicine & Biotech.
• Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
• Terray Therapeutics — Guided by our powerful AI capabilities, Terray leverages vast high-quality data to optimize the path from discovery to transformative therapeutics.

Portfolio highlights

• Castelion — We are a modern defense production company building the next generation of military hypersonic, vehicle, and strike systems to deter future wars.
• Headway — Headway is a mental healthcare system provider based in New York. It develops a health insurance advisory platform designed to connect patients with therapists and provides administrative support to therapists who don’t typically accept insurance. The company was founded by Andrew Adams, Jake Sussman, Dan Ross, and Kevin Chan in 2019.
• Blackbird — We believe the next great hospitality technology platform should connect restaurants and their customers directly, in meaningful and ongoing ways. Blackbird is founded by a team with a passion for restaurants and a track record of using technology to solve problems.

Portfolio highlights

• Invirsa — Invirsa is developing a unique, broad platform based on a naturally occurring small molecule (INV-102) that has demonstrated enhanced immune response to infection. INV-102 not only reduces viral infection, and potentially bacterial replication, it also reduces inflammation, while enhancing the bodies wound healing response. Invirsa'stechnology is first being developed in the ophthalmology and pulmonary space.Invirsa’s technology has the potential to be a first line therapy for common infectious diseases, whether it's the 100 million viral pulmonary infections or the 5 million infectious conjunctivitis cases that occur every year in the US alone.
• MentorcliQ — Mentoring programs that drive employee engagement, development, and retention with MentorcliQ's award-winning mentoring software and approach. See why our customers love us!
• SureImpact — SureImpact is a user-friendly, social services case management software that helps you track and report outcomes, measure participant needs, and demonstrate impact to funders.

Portfolio highlights

• Midi Health — Expert care for women 40+. Made for midlife. Delivered by experienced clinicians. Covered by insurance. Book a visit today.
• Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
• ROME Therapeutics — ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier inbiology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning.

Portfolio highlights

• Solu Therapeutics — Solu Therapeutics is a precision-medicine-focused company developing therapeutics to eliminate disease-driving cells.
• Photys Therapeutics — Photys Therapeutics is a proprietary chimeric small molecules platform company, developing a new class of medicines for precise control of protein function.
• Sitryx Therapeutics — Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism.Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.

Portfolio highlights

• Meeno — Meeno is a relationship mentoring app powered by generative AI
• Rocket.Chat — Explore Rocket.Chat, where we put data privacy into every conversation and enable teams to collaborate seamlessly.
• Pulumi — Pulumi's open source infrastructure as code SDK enables you to create, deploy, and manage infrastructure on any cloud, using your favorite languages.

Portfolio highlights

• Ronovo Surgical — Founded in 2019 and headquartered in Shanghai, Ronovo Surgical is founded by industry veterans from global leaders in surgical and industrial robotics, such as Intuitive Surgical, Johnson & Johnson, Medtronic and KUKA. Aiming to transform how surgery is performed in China, Ronovo is leveraging robust R&D capabilities and strategicpartnerships globally to accelerate the development of a broad portfolio of MIS and digital surgery solutions that exemplifies the core themes of simplicity, precision, and intelligence.
• COMPASS Pathways — COMPASS is a mental health care company dedicated to accelerating patient access and experience to evidence-based innovation in mental health care.
• ADARx Pharmaceuticals — ADARx is a genetic medicine company focusing on the editing of Messenger RNA Targeting transcripts and oligonucleotide-based therapeutics.

Portfolio highlights

• Harpe Bio — Harpe Bioherbicide Solutions is a Raleigh-based company that provides sustainable weed-management solutions for organic and industrial agriculture. The company was founded in 2020 by Chad Brommer and is headquartered in Raleigh, North Carolina, United States.
• MEND — Mend is the scientifically proven way to heal and enhance your body faster.
• Pluton Biosciences — The miniscule organisms Pluton Biosciences discover possess the power to create global change. Pluton quickly and inexpensively taps into the diverse world of bacteria, fungi and viruses to discover next-generation products for carbon sequestration, agriculture, pharmaceutical, biomaterials and bioremediation.Pluton Bioscience's discoveryprocess generates diverse commercialization options, including: Organisms (biological products), Small Molecule Chemistries (fermentable and non-fermentable) and New Traits (scale dependent).

Portfolio highlights

• Siren Biotechnology — Siren Biotechnology blends two revolutionary therapeutic technologies into one for a novel approach to treating cancer.AAV gene therapy and cytokine immunotherapy are two revolutionary treatment approaches that Siren Biotechnology has combined into a single, redesigned modality. This approach overcomes significant obstacles and entirely transformshow tumor cells are eliminated and anti-tumor immunity is stimulated.
• Foresight Diagnostics — Foresight Diagnostics develops novel technology created to detect cancers earlier from a simple blood draw.
• Range Biotechnologies — We're dedicated to making health monitoring a reality. We develop tools that capture the molecular state of individuals to prevent disease and improve health.

Portfolio highlights

• BioLoomics — BioLoomics is a preclinical stage biotechnology company that uses evolution in a microscope to develop drug discovery tools and protein drugs. Our VariVolve platform tests millions of protein designs for a targeted activity in hours, enabling efficient mining of the vast chemical space of protein designs. A strong advantage of our approach is theuse of whole intact cells as test vessels that capture complex drug behavior not attainable in conventional assays.
• Erthos — erthos is a producer of biodegradable packaging materials intended to replace traditional polystyrene and polypropylene inputs.
• ZeroAvia — ZeroAvia is producing the world's first practical zero emission aviation powertrain, initially targeting 20-seat airplanes to start replacing dirty jet fuel in regional transport

Portfolio highlights

• Aethon Therapeutics — Aethon Therapeutics treats cancer by combining immunotherapy and targeted treatment to increase its effectiveness. Aethon's unique anti-drug-peptide conjugate/MHC antibodies are intended to be employed in conjunction with TCI of RAS, EGFR, and other cancer-associated mutations.
• Ascidian Therapeutics — Ascidian is redefining the treatment of disease by rewriting RNA.
• Galvanize Therapeutics — Galvanize Therapeutics is an energy-based medical device technology that provides therapeutic products and services to deliver healthcare solutions. The company aims to become the global leader in delivering medical technology innovations that drive biological processes to treat a range of diseases, starting with treating chronic bronchitissymptoms, cardiac arrhythmias, and solid tumors.It was formed by Apple Tree Partners in 2022.

Portfolio highlights

• Ozlo Sleep — Ozlo Sleep is a science-driven sleep and audio technology company that supports and simplifies sleep rituals for clinical benefits, without the use of medication.
• Affect Therapeutics — We beat addiction by changing the game. A smartphone app for drug and alcohol addiction puts an integrated digital treatment program in your pocket.
• Range Biotechnologies — We're dedicated to making health monitoring a reality. We develop tools that capture the molecular state of individuals to prevent disease and improve health.

Portfolio highlights

• evonetix — evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniqueswe are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines.
• Pharvaris — Pharvaris is a clinical-stage company focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.
• Galileo — Galileo: Our dedicated clinicians are on call 24/7 to provide full-spectrum medical care, from urgent to chronic, across digital and in-person settings.

Portfolio highlights

• Boxbot — Dynamic storage and retrieval platform that adapts to varying cubic dimensions and eliminates manual pick stations.
• d-Matrix — d-Matrix takes a clean-slate approach to AI compute efficiency, solving some of the most teething problems for the largest datacenter customers in the world.
• Phasecraft — Using disruptive theory to unlock the power of quantum computing

Portfolio highlights

• Parallel Bio — Parallel Bio uses human immune organoids to accelerate the discovery and development of treatments.
• TFC Therapeutics — TFC Therapeutics is a biotechnology company developing novel biologics to target and eliminate key drivers of cancer.
• EnPlusOne Biosciences — EnPlusOne Biosciences provides innovative solutions for emerging RNA therapeutics.

Portfolio highlights

• DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team News See more Our Work OUR APPROACH ABOUT DIABETES
• NMD Pharma — NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.Importantly, the approach improves neuromuscular transmission in a way that ispotentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.
• Bonum Therapeutics — Bonum Therapeutics is focused on a proven technology that utilizes allosteric regulation to create targeted, highly active, and less toxic medicines.

Portfolio highlights

• OOVA — OOVA is a fertility diagnostic company that spun out from Mount Sinai Hospital in New York City. Using patent pending biochemistry and artificial intelligence, OOVA learns a woman’s fertility profile by accurately measuring key hormones over time through daily urine samples. By monitoring this critical balance of hormones, OOVA can help a woman getpregnant, identify reasons she is having trouble getting pregnant, and even expose reproductive health issues like PCOS.
• Raise Green — Raise Green is the climate tech marketplace for local impact investing licensed with the SEC and FINRA to sell private securities.
• Driver Technologies — Turn your phone into a dash cam.

Portfolio highlights

• Indigo — Indigo Ag improves farmer profitability, environmental sustainability, and consumer health through the use of natural microbiology and digital technologies in agriculture.
• Harbinger Health — Harbinger Health is a biotechnology company that develops a two-tier testing model for the detection of early cancer with a blood test. The company combines artificial intelligence with insights into the biology of the beginnings of cancer to identify cancer before it is visible or symptomatic with the aim of developing low-cost, multi-cancer bloodtests.
• Generate Biomedicines — Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines.

Portfolio highlights

• Cerevance — Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle theearly onset of various neurological diseases.
• OncoResponse — OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery. The company licensed the I-STAR™ platform, developed and validated by Theraclone Sciences of Seattle, tointerrogate the human memory B-cell repertoire of cancer patients who are considered “Elite Responders” to immunotherapy; as such, their own adaptive immune system responded to immunotherapy stimulation in a way that achieved curative or durable responses. From these Elite Responders, OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody derived therapeutics for the treatment of cancer.
• Larkspur Biosciences — Larkspur's strategy focuses on the particular ways in which tumours hijack the immune system by developing precision immunotherapies for molecularly defined patient groups to overcome the bottlenecks that allow the tumour to subvert the immune system.

Portfolio highlights

• Acesion Pharma — Acesion Pharma ApS is a Danish biotech company founded in 2011 and based in Copenhagen. Acesion Pharma develops more efficacious and safe drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia.
• Actio Biosciences — At Actio, we are leveraging advances in genetics and precision medicine to develop life-changing treatments that target underlying shared biology between rare and common diseases. We are applying expertise in genetics, drug discovery, and data sciences to pinpoint targets that not only cause rare diseases with high unmet need, but that also hold promise in more common indications.
• Diligent Robotics — We build robots like Moxi that assist hospital staff with routine activities so they can focus on caring for patients.

Portfolio highlights

• Nitrase Therapeutics — Nitrase Therapeutics is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is onParkinson's disease, the company aims to expand its proprietary platform to include other disease indications.
• Quanta Therapeutics — Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA.
• AmbAgon Therapeutics — AmbAgon Therapeutics is a developer of cancer molecule therapeutics. The company offers research of a small molecule that augments a tumor-suppressing protein. AmbAgon Therapeutics was founded by Christian Ottmann, Lucas Brunsveld, and Michelle Arkin.

Portfolio highlights

• Melonfrost — Melonfrost has created a novel way to optimize strains, eliminating the biggest bottleneck in the bioeconomy. By combining machine learning and evolution, our proprietary AI + Hardware platform steers the evolution of cells in real-time. Our algorithms explore the biological space and make decisions, while innovations in robotics, sensing, fluidicsand environmental control replace scientific labor, shaving years off the time to market for bioproducts. Evolution, from millenia to months.
• Hyfé — Hyfé Foods is a biotech company producing ingredients by leveraging fungal fermentation to upcycle water byproducts from food manufacturers.
• Macro Oceans — Macro Oceans develops technology to harness the restorative power of seaweed.

Portfolio highlights

• DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team News See more Our Work OUR APPROACH ABOUT DIABETES
• SAB Biotherapeutics — A biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems,rare conditions, long-term diseases and global pandemic threats.
• Veralox Therapeutics — Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.

Portfolio highlights

• Cymbal — The human readable block explorer. Explore any wallet, NFT or collection to understand their activity, all in real time.
• Spline — Spline is a free 3D design software with real-time collaboration to create web interactive experiences in the browser. Easy 3d modeling, animation, textures, and more.
• Ossium Health — Ossium is building the world's first bone marrow bank to treat blood cancers, improve organ transplantation, and repair damage from radiation.The cells of the immune system are the human body’s natural defenders against disease. At Ossium, they are developing better methods of recovering, preserving, deploying these critical cells to keepdisease at bay.

Portfolio highlights

• Pluton Biosciences — The miniscule organisms Pluton Biosciences discover possess the power to create global change. Pluton quickly and inexpensively taps into the diverse world of bacteria, fungi and viruses to discover next-generation products for carbon sequestration, agriculture, pharmaceutical, biomaterials and bioremediation.Pluton Bioscience's discoveryprocess generates diverse commercialization options, including: Organisms (biological products), Small Molecule Chemistries (fermentable and non-fermentable) and New Traits (scale dependent).
• Attovia Therapeutics — Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients in being treated.
• Lightcast Discovery — Flexible control over droplet number, occupancy, location and movement. Enabling efficient, multi-step workflows with unprecedented flexibility.

Portfolio highlights

• Abivax — Abivax recently presented impressive 9-month interim extension data from studies of ABX464 in ulcerative colitis during an oral presentation at DDW 2019, demonstrating a continued duration of beneficial effect in patients after 11-months of treatment. View the conference presentation, here:
• Lusaris Therapeutics — Lusaris Therapeutics develops small-molecule neuroplastogen therapeutics for neuropsychiatric and neurological disorders.
• SpringWorks Therapeutics — We relentlessly pursue every possibility to create new cancer breakthroughs and power our approach with people who think hard, care hard, and act with urgency. %

Portfolio highlights

• SigNoz — SigNoz is an open-source observability tool to help you find issues in your deployed applications & solve them quickly. It provides logs, metrics, and traces under a single pane of glass. Built with ClickHouse as datastore, it is designed to handle enterprise scale.
• teachme.to — Teachme.to is a community of learners discovering lessons for everything.
• Canid — We believe vaccinating shouldn't be hard and it shouldn't be a distraction from what's most important: taking care of the kids.

Portfolio highlights

• ARTBIO — ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines. ARTBIO is changing cancer care by creating a new class of alpha radioligand therapeutics (ART) and the ecosystem that supports.
• Upstream Bio — Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma. Upstream Bio was founded in 2004 and was headquartered in the United States.
• Bicara Therapeutics — Bicara enables access to the thriving innovation ecosystem which accelerates our development of therapies for cancer. Synergies between the Bicara teams in Boston and Bengaluru will pioneer breakthrough innovation.

Portfolio highlights

• Cerby — Collaborate without chaos. Cerby helps your team be productive while protecting your brand. Secure unmanageable applications. Only with Cerby.
• Raincoat — Get the policy that offers you cash after the hurricane, without deductibles or having to make claims!
• Hyper — Hyper is an avatar-based social network. We're building the metaverse.

Portfolio highlights

• Synthekine — Discovering, Developing and Commercializing the Next Generation of Selective Cytokine Therapeutics. We believe that cytokine therapeutics engineered to be selective can fundamentally change the treatment paradigm of cancer and inflammatory disease.
• Cajal Neuroscience — Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.
• Carmot Therapeutics — Drug discovery and development to target the root causes that drive cancer and metabolic diseases using Chemotype Evolution.

Portfolio highlights

• Therini Bio — Therini Bio is developing novel therapeutics based insights into the role of fibrin in driving chronic innate immune activation.
• MooveAI — MooveAI is an automotive company that provides innovative solutions in end-to-end, predictive road intelligence analytics. Their first approach involves continuously collecting trillions of data points about road networks, including data about connected vehicles, road attributes, such as friction and traffic. The data is then integrated into ourproprietary location analytics platform, where it is verified and analyzed. Finally, actionable insights are provided in the form of road risk scores that describe the relative safety of millions of individual road segments.
• Sharrow Marine — Sharrow Marine is a wholly owned subsidiary of sharrow engineering, a company that develops high-performance propulsion technology for the maritime and aeronautical industries. Their sharrow propeller has applications in all types of commercial marine shipping, aerospace, aviation, industrial and commercial non-propulsion uses, as well as inrecreational marine use.

Portfolio highlights

• OncoResponse — OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery. The company licensed the I-STAR™ platform, developed and validated by Theraclone Sciences of Seattle, tointerrogate the human memory B-cell repertoire of cancer patients who are considered “Elite Responders” to immunotherapy; as such, their own adaptive immune system responded to immunotherapy stimulation in a way that achieved curative or durable responses. From these Elite Responders, OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody derived therapeutics for the treatment of cancer.
• Venture Med Group — VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients.Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly costeffective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device.
• Spruce Biosciences — Developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need